Camurus AB (publ) (0RD1.L)

501,95 +6,17 (+1,25%) Börsenschluss: 05:39PM BST

Camurus AB (publ)

Ideon Science Park
Lund 223 70
Sweden
46 4 62 86 57 30
https://www.camurus.com

Sektor(en): 
Branche: 
Vollzeitmitarbeiter: 213

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Fredrik Tiberg	President, CEO, CSO & Director	12,06M	N/A	1963
Mr. Jon U. Garay Alonso	Chief Financial Officer	N/A	N/A	1973
Mr. Torsten Malmstrom	Chief Technology Officer	N/A	N/A	1968
Mr. Rein Piir B.Sc.	Vice President of Investor Relations	N/A	N/A	1958
Ms. Maria Lundqvist	Global Head of Human Resources	N/A	N/A	1966
Mr. Markus Johnsson	Senior Vice President of R&D	N/A	N/A	1972
Mr. Fredrik Joabsson	Chief Business Development Officer	N/A	N/A	1972
Mr. Richard Jameson	Chief Commercial Officer	N/A	N/A	1964
Mr. Alberto M. Pedroncelli	Chief Medical Officer	N/A	N/A	1964

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in SEK.

Beschreibung

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain and Brixadi to treat opioid use disorder. Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; and Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity, as well as licensing agreement with Solasia Pharma. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden. The company operates as a subsidiary of Sandberg Development AB.

Corporate Governance

Camurus AB (publ)s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 4. Die grundlegenden Scores sind Audit: 8, Vorstand: 6, Shareholderrechte: 1, Kompensation: 4.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.